Case report: 18F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient.
Front Oncol
; 12: 1095779, 2022.
Article
in En
| MEDLINE
| ID: mdl-36620595
Full text:
1
Database:
MEDLINE
Type of study:
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Front Oncol
Year:
2022
Type:
Article
Affiliation country:
China